Clinical trials: sponsored by Baylor Research Institute
Gastrointestinal Diseases
Foregut Leaks-Role of Microbiome
Aims 1. To understand the microbial composition involved with foregut leaks 2. To define the virulence changes in the microbiota following foregut leaks 3.
- Trial name
- NCT07424469
- Testing
- Biopsy and fluid samples
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor Research Institute
Wound Edges
Intraoperative CO₂ (Carbon Dioxide)
To evaluate whether intraoperative fractionated CO₂ laser treatment of surgical wound edges improves postoperative scar appearance compared with untreated wound edges following Mohs micrographic surgery (MMS).
- Trial name
- NCT07592468
- Testing
- CO2 Fractionated Laser, Non CO2 Laser Treatment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor Research Institute
Chronic Kidney Disease, Type 2 Diabetes
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.
- Trial name
- RAPID-CKD (NCT07547878)
- Testing
- Finerenone, Semaglutide, Lotensin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Baylor Research Institute
Aging, Longevity
Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults.
- Conditions
- Aging, Longevity, Biomarkers of Aging
- Trial name
- LONG-LIFE (NCT07719088)
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Charles Raison
Skin Substitutes, Secondary Intention Healing
Skin Subs vs Secondary Intention
The purpose of this study is to compare two ways of caring for wounds after Mohs micrographic surgery (MMS) for skin cancer using skin substitutes and secondary intention healing, to determine which option leads to better healing…
- Conditions
- Skin Substitutes, Secondary Intention Healing, Skin Cancer Healing
- Trial name
- NCT07587749
- Testing
- Skin Substitute, Secondary Intention Healing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor Research Institute
Stroke, Acute, Stroke
Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)
Investigators will conduct a randomized controlled trial (RCT) to assess intervention efficacy of telehealth delivery of the GLB-CVA (tGLB-CVA) compared to a 6-month wait-list control (WLC) in partnership with a diverse group of…
- Conditions
- Stroke, Acute, Stroke, Stroke, Cardiovascular, Stroke (CVA) or TIA
- Trial name
- tGLB-CVA (NCT06569121)
- Testing
- Group Lifestyle Balance for People Post Stroke (GLB-CVA)
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Baylor Research Institute
Acute Myeloid Leukemia
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment.
- Trial name
- NCT04219163
- Testing
- CLL-1.CAR T cells
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Baylor College of Medicine
Spinal Cord Injuries
Dosing of Overground Robotic Gait Training With Functional Outcomes and Neuroplasticity After Spinal Cord Injury
The DOOR SCI project examines dosing effects of robotic gait training (RGT) and transcranial magnetic stimulation (TMS) initiated during inpatient rehabilitation and continued through early outpatient rehabilitation
- Trial name
- DOORSCI (NCT05218447)
- Testing
- Robotic Gait Training, Usual Care (UC) Gait Training
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Baylor Research Institute
Graft-versus-host-disease (GVHD), Gastrointestinal
Vitamin C With Steroids for Gastrointestinal GVHD
After a transplant from another donor, one risk is graft versus host disease (GVHD) that happens because of differences between the donated cells (graft) and the patient's body cells (host).
- Trial name
- NCT07197749
- Testing
- Vitamin C (Ascorbic Acid)
- Volunteers
- 35 people
- Sponsor
- Baylor College of Medicine
Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer.
- Trial name
- NCT06008275
- Testing
- Neratinib Oral Tablet, Ruxolitinib Oral Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia
- Trial name
- HAPLOTAB (NCT05236764)
- Testing
- CliniMACS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Aging, Preventive Care
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
This study consists of three aims focused on examining the feasibility of adding the Geriatric Resources and Assessment for the Care of Elders (GRACE) model to structured Annual Wellness Visits (AWVs) to improve patient and…
- Conditions
- Aging, Preventive Care, Multimorbidity, Palliative Care
- Trial name
- SPIRE2 (NCT07166861)
- Testing
- Annual Wellness Visit, Annual Wellness Visits + Geriatric Resources and Assessment for the Care of Elders (AWV + GRACE)
- Where
- 4 sites in United States
- Volunteers
- 7,140 people
- Sponsor
- Massachusetts General Hospital
Lymphoma, Myeloma
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment.
- Conditions
- Lymphoma, Myeloma, Leukemia
- Trial name
- CHARKALL (NCT00881920)
- Testing
- Kappa CD28 T cells
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Baylor College of Medicine
Multiple Myeloma
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM).
- Trial name
- TACTAM (NCT02291848)
- Testing
- TAA-specific CTLs, TAA-specific CTLs- fixed dose
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
B Cell Lymphoma, Chronic Lymphocytic Leukemia
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Patients on this study have a type of lymph gland cancer called non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "Lymphoma" or "Leukemia").
- Conditions
- B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- CRETI-NH (NCT00586391)
- Testing
- CD19CAR-28-zeta T cells, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Baylor College of Medicine
Non-Hodgkin's Lymphoma, B-Cell ALL
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Patients have a type of lymph gland cancer called Non-Hodgkin Lymphoma (NHL), acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL) (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
- Trial name
- CARPASCIO (NCT02050347)
- Testing
- CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Baylor College of Medicine
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer.
- Trial name
- RELY-30 (NCT02917083)
- Testing
- CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Baylor College of Medicine
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not…
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma
- Trial name
- CABAL2 (NCT06176690)
- Testing
- C7R.CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Patients will be receiving a stem cell transplant as treatment for their disease. As part of the stem cell transplant, patients will be given very strong doses of chemotherapy, which will kill all their existing stem cells.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia
- Trial name
- DOTTI (NCT01494103)
- Testing
- iCaspase9-transduced T cells, AP1903
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- SAGAN (NCT01853631)
- Testing
- Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine